Intended for healthcare professionals

  1. Research
  2. Cost effectiveness of...
  3. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines
CCBYNC Open access
Research

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2509 (Published 02 June 2010) Cite this as: BMJ 2010;340:c2509

Data supplement

  • Web Extra

    Extra material supplied by the author

    Files in this Data Supplement:

    • Data Supplement - Web extra 1 Condition specific utility weights and related costs
    • Data Supplement - Web extra 2 Indirect effects in the analysed birth cohort
    • Data Supplement - Web extra 3 Indirect effects for individuals aged 5 years or older
    • Data Supplement - Web extra 4 Reduced dose schedules
    • Data Supplement - Web table A Hospital admissions for pneumonia and general practitioner visits for non-invasive pneumonia and acute otitis media per 100â��000 per age category
    • Data Supplement - Web table B Direct average hospital admission cost for invasive pneumococcal disease on the basis of the average duration of hospital stay (both intensive care and general ward days) and corresponding unit costs

Related articles

See more

Cited by...

  • Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India
  • Cost-Effectiveness of Using 2 vs 3 Primary Doses of 13-Valent Pneumococcal Conjugate Vaccine
  • Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
  • Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil
Back to top